Biological Markers of Alzheimer’s Disease

1. Front Matter

   Pages I-XV

   PDF

2. Cerebrospinal Fluid Neurochemical Markers in Alzheimer’s Disease

   • J. R. Atack

   Pages 1-16

3. Potential Diagnostic Markers for Alzheimer’s Disease

   • P. Davies

   Pages 17-22

4. Cerebrospinal Fluid-Based Laboratory Test for Alzheimer’s Disease

   • H. M. Wisniewski, P. D. Mehta, K. S. Kim, G. S. Merz

   Pages 23-29

5. Probes for the Molecular Components of Plaques and Tangles Point to a Broadening View of Alzheimer Pathology

   • K. S. Kosik, D. J. Selkoe

   Pages 30-38

6. Tau 64 and Tau 69: Two Early Biochemical Markers of Neurofibrillary Degeneration

   • A. Delacourte, S. Flament, A. Défossez, L. Buee, B. Hémon, M. Parent et al.

   Pages 39-55

7. A cDNA Encodes Epitopes Shared Between Microtubule-Associated Protein MAP2 and Alzheimer Neurofibrillary Tangles: In Situ Hybridization and Immunocytochemistry

   • J. P. Brion, A. M. Couck, M. E. Cheetham, D. Hanger, B. H. Anderton, J. Flament-Durand

   Pages 56-65

8. Epitopes Characteristic of Paired Helical Filaments Demonstrated in Microglial Cells and Macrophages of the Meninges: A Possible Laboratory Diagnosis of Alzheimer’s Disease from Cerebrospinal Fluid?

   • J. Ulrich, S. Ipsen, A. Probst, J. P. Brion

   Pages 66-72

9. Relationship Between Tau, Paired Helical Filaments, Amyloid and the Intellectual Deterioration in the Neocortex in Normal Aging and in Senile Dementia of the Alzheimer Type

   • P. Delaère, C. Duyckaerts, J. P. Brion, F. Piette, J.-J. Hauw

   Pages 73-82

10. Molecular Insights into Alzheimer’s Disease

    • J. W. Pettegrew

    Pages 83-104

11. Altered Protein Kinase and Amyloid ß-Protein Precursor in Alzheimer’s Disease: Which Comes First?

    • T. Saitoh, D. S. Iimoto

    Pages 105-117

12. The Amyloid Gene of Alzheimer’s Disease and Neuronal Dysfunction

    • J. M. Salbaum, C. L. Masters, K. Beyreuther

    Pages 118-122

13. Cloning of Different Amyloid Peptide Precursors from Brains of Patients with Alzheimer’s Disease

    • F. de Sauvage, A. F. Macq, J. M. Maloteaux, J. N. Octave

    Pages 123-129

14. Genetic Studies of the Alzheimer’s Disease-Associated Amyloid β-Protein Precursor Gene and Familial Alzheimer’s Disease

    • R. E. Tanzi, P. St. George-Hyslop, M. James, J. L. Haines, J. F. Gusella

    Pages 130-137

15. Alzheimer’s Disease and Chromosome 21

    • A. R. Haynes, M. J. Owen, A. M. Goate, L. A. James, M. J. Mullan, R. Williamson et al.

    Pages 138-145

16. Calcium and the Cytoskeleton in Alzheimer’s Disease

    • M. L. Shelanski

    Pages 146-152

17. Use of Cultured Skin Fibroblasts in Studies of Alzheimer’s Disease

    • J. P. Blass, A. C. Baker, K.-F. R. Sheu, L. Ko, R. S. Black, A. Smith

    Pages 153-162

18. Lactate Production and Glycolytic Enzymes in Skin Cultured Cells from Alzheimer’s Disease Patients

    • S. Sorbi, M. Mortilla, S. Piacentini, G. Tesco, S. Tonini, L. Amaducci

    Pages 163-166

19. Back Matter

    Pages 167-169

    PDF

This volume presents the proceedings of the symposium held in Toulouse on April 24, 1989, on the topic "Biological Markers of Alzheimer's Disease. " This sym­ posium was the fourth of a continuing and successful series of Colloques Medecine et Recherche organized by the Fondation IPSEN pour la Recherche Therapeutique, addressing various aspects of contemporary research in the field of Alzheimer's disease (AD). The series started in September 1987 with "Im­ munology and Alzheimer's Disease," followed 6 months later in Paris by "Gene­ tics and Alzheimer's Disease" and in September 1988 in Montpellier by "Neuronal Grafting and Alzheimer's Disease. " The present symposium was organized for the purpose of gathering the most current ideas concerning biological markers of AD. The papers presented at this symposium may be roughly subdivided into three groups. The first deals with the markers of AD at the level of the brain itself. These markers are studied either through the cerebrospinal fluid or through techniques such as nuclear magnetic resonance (NMR) - approaches which respectively aim at demonstrating the cerebral changes indicated by the debris resulting from the disease, or studying the possible neurochemical abnormalities that occur in the earlier stages of AD.

• Alzheimer's disease
• Alzheimer-Krankheit
• Alzheimer´s disease
• biologische Marker
• blood
• brain
• cortex
• dementia
• diagnosis
• magnetic resonance
• nuclear magnetic resonance (NMR)
• pathogenesis
• patients
• research
• skin

• Inserm U324, Paris, France

  François Boller

• University of California at San Diego, La Jolla, USA

  Robert Katzman

• Hôpital Purpan, Toulouse, France

  André Rascol

• Hôpital Salpêtrière, Paris, France

  Jean-Louis Signoret

• Fondation IPSEN pour la Recherche Thérapeutique, Paris Cédex, France

  Yves Christen

Policies and ethics